Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

被引:186
作者
Fukuda, T
Hackman, RC
Guthrie, KA
Sandmaier, BM
Boeckh, M
Maris, MB
Maloney, DG
Deeg, HJ
Martin, PJ
Storb, RF
Madtes, DK
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Program Pulm Crit Care Med, Seattle, WA 98109 USA
[2] Univ Washington, Sch Med, Dept Pathol & Lab Med, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2003-05-1597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic pneumonia syndrome (IPS) is a significant noninfectious complication of hematopoietic stem cell transplantation (HSCT). We compared the incidences and outcomes of IPS among patients who underwent allogeneic HSCT after nonmyeloalblative (n = 183) compared with conventional (n = 917) conditioning between December 1997 and December 2001. Patients given nonmyeloalblative conditioning were older than those given conventional conditioning (median ages, 53 vs 41 years; P = .001). The cumulative incidence of IPS was significantly lower at 120 days after nonmyeloalblative conditioning than conventional conditioning (2.2% vs 8.4%; P = .003). In addition, greater patient age (older than 40 years), diagnosis of acute leukemia or myelodysplastic syndrome, and severe acute graft-versus-host disease were associated with significantly increased risks for IPS. Among older patients (older than 40 years) given conventional conditioning, high-dose total body irradiation (TBI) was associated with an increased risk for IPS than were non-TBI-based regimens (16% vs 5.8%; P = .001). IPS occurred early after transplantation, progressed rapidly, and was associated with a high mortality rate (75%) despite aggressive support. initiation of mechanical ventilation and the presence of renal insufficiency at IPS onset were associated with increased risks for death after IPS. These findings support the concept that lung damage from the conditioning regimen plays a crucial role in the development of IPS after HSCT. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:2777 / 2785
页数:9
相关论文
共 52 条
[21]   Protected specimen brush or bronchoalveolar lavage to diagnose bacterial nosocomial pneumonia in ventilated adults: A meta-analysis [J].
de Jaeger, A ;
Litalien, C ;
Lacroix, J ;
Guertin, MC ;
Infante-Rivard, C .
CRITICAL CARE MEDICINE, 1999, 27 (11) :2548-2560
[22]   CYCLOSPORINE AS PROPHYLAXIS FOR GRAFT-VERSUS-HOST DISEASE - A RANDOMIZED STUDY IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOBLASTIC LEUKEMIA [J].
DEEG, HJ ;
STORB, R ;
THOMAS, ED ;
FLOURNOY, N ;
KENNEDY, MS ;
BANAJI, M ;
APPELBAUM, FR ;
BENSINGER, WI ;
BUCKNER, CD ;
CLIFT, RA ;
DONEY, K ;
FEFER, A ;
MCGUFFIN, R ;
SANDERS, JE ;
SINGER, J ;
STEWART, P ;
SULLIVAN, KM ;
WITHERSPOON, RP .
BLOOD, 1985, 65 (06) :1325-1334
[23]   Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome [J].
Deeg, HJ ;
Storer, B ;
Slattery, JT ;
Anasetti, C ;
Doney, KC ;
Hansen, JA ;
Kiem, HP ;
Martin, PJ ;
Petersdorf, E ;
Radich, JP ;
Sanders, JE ;
Shulman, HM ;
Warren, EH ;
Witherspoon, RP ;
Bryant, EM ;
Chauncey, TR ;
Getzendaner, L ;
Storb, R ;
Appelbaum, FR .
BLOOD, 2002, 100 (04) :1201-1207
[24]   Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation [J].
Della Volpe, A ;
Ferreri, AJM ;
Annaloro, C ;
Mangili, P ;
Rosso, A ;
Calandrino, R ;
Villa, E ;
Lambertenghi-Deliliers, G ;
Fiorino, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (02) :483-488
[25]   HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE FOLLOWED BY ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS WITH LYMPHOID MALIGNANCIES WHO HAD RECEIVED PRIOR DOSE-LIMITING RADIATION-THERAPY [J].
DEMIRER, T ;
WEAVER, CH ;
BUCKNER, CD ;
PETERSEN, FB ;
BENSINGER, WI ;
SANDERS, J ;
CLIFT, RA ;
LILLEBY, K ;
ANASETTI, C ;
MARTIN, P ;
STORB, R ;
CHAUNCEY, T ;
DONEY, K ;
SULLIVAN, K ;
APPELBAUM, FR .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :596-602
[26]  
FORMAN SJ, 1987, TRANSPLANT P, V19, P2605
[27]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[28]  
GRANENA A, 1993, BONE MARROW TRANSPL, V11, P453
[29]   Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation:: a meta-analysis [J].
Hartman, AR ;
Williams, S ;
Dillon, JJ .
BONE MARROW TRANSPLANTATION, 1998, 22 (05) :439-443
[30]   MARROW TRANSPLANTATION FOR LEUKEMIA FOLLOWING FRACTIONATED TOTAL-BODY IRRADIATION - A COMPARATIVE TRIAL OF METHOTREXATE AND CYCLOSPORINE [J].
IRLE, C ;
DEEG, HJ ;
BUCKNER, CD ;
KENNEDY, M ;
CLIFT, R ;
STORB, R ;
APPELBAUM, FR ;
BEATTY, P ;
BENSINGER, W ;
DONEY, K ;
CHEEVER, M ;
FEFER, A ;
GREENBERG, P ;
HILL, R ;
MARTIN, P ;
MCGUFFIN, R ;
SANDERS, J ;
STEWART, P ;
SULLIVAN, K ;
WITHERSPOON, R ;
THOMAS, ED .
LEUKEMIA RESEARCH, 1985, 9 (10) :1255-1261